SUMMARY
Hematopoietic stem and progenitor cells (HSPCs) tightly couple maintenance of the bone marrow (BM) reservoir, including undifferentiated long-term repopulating hematopoietic stem cells (LT-HSCs), with intensive daily production of mature leukocytes and blood replenishment. We found two daily peaks of BM HSPC activity that are initiated by onset of light and darkness providing this coupling. Both peaks follow transient elevation of BM norepinephrine and TNF secretion, which temporarily increase HSPC reactive oxygen species (ROS) levels. Lightinduced norepinephrine and TNF secretion augments HSPC differentiation and increases vascular permeability to replenish the blood. In contrast, darkness-induced TNF increases melatonin secretion to drive renewal of HSPCs and LT-HSC potential through modulating surface CD150 and c-Kit expression, increasing COX-2/aSMA + macrophages, diminishing vascular permeability, and reducing HSPC ROS levels. These findings reveal that light-and darkness-induced daily bursts of norepinephrine, TNF, and melatonin within the BM are essential for synchronized mature blood cell production and HSPC pool repopulation.
INTRODUCTION
Bone marrow (BM)-resident hematopoietic stem and progenitor cells (HSPCs) intensively produce and replenish the blood daily with new mature blood and immune cells with a finite lifespan while preserving the pool of undifferentiated stem cells, including long-term repopulating hematopoietic stem cells (LT-HSCs) . Shifting between these dual HSPC functions is regulated by signals originating from various cell types residing in the BM microenvironment and by external light and dark cycles (Mendelson and Frenette, 2014; Yu and Scadden, 2016) . These signals activate HSPCs, regulating their metabolism and function. Increased reactive oxygen species (ROS) are major regulators of HSPC migration and development (Ludin et al., 2012 (Ludin et al., , 2014 . Light and dark cycles are translated by neural and hormonal cues, including sympathetic output and melatonin, and are implicated in bone turnover (Fu et al., 2005; Simmons and Nichols, 1966) , host immunity and inflammation (Curtis et al., 2014; Man et al., 2016; Borniger et al., 2017) , and neutrophil clearance (Casanova-Acebes et al., 2013) .
HSPC egress from the BM to the blood is regulated by elevated morning norepinephrine (NE) release by the nervous system in response to daylight and reduced BM CXCL12 levels (Lucas et al., 2008; Mé ndez-Ferrer et al., 2008) . HSPC egress is also regulated daily by corticosterone (Kollet et al., 2013) and complement activation (Borkowska et al., 2016) . The balance between BM CXCL12 and blood sphingosine 1-phosphate (S1P) dynamically regulates HSPC recruitment to the circulation versus their BM retention (Golan et al., 2013) .
Tumor necrosis factor (TNF) is a major inflammatory cytokine that is mostly secreted by activated leukocytes in a daily rhythm manner (Arjona and Sarkar, 2005; Bissonnette et al., 1995) . TNF also regulates HSPCs, which functionally express its receptors (Dybedal et al., 2001; Pronk et al., 2011; Rezzoug et al., 2008) . The darkness hormone melatonin is synthesized by the pineal gland and by BM cells (Conti et al., 2000; Mias et al., 2008; Tan et al., 1999) , exerting anti-oxidative and immunomodulatory functions (Carrillo-Vico et al., 2013) .
To reveal how the BM HSPC reservoir is maintained, we examined the kinetics of daily light and dark cues and revealed the major players involved. We identified two major daily BM HSPC peaks (morning and night) with different functions. The morning peak increased HSPC proliferation, differentiation, egress, and blood replenishment, whereas the night peak mediated HSPC maintenance and replenishment of the BM stem cell pool.
RESULTS

Light-and Dark-Mediated BM HSPC Proliferation Peaks Are Driven by TNF and ROS Elevations
To understand how the daily 11 a.m. HSPC release peak (Mé ndez-Ferrer et al., 2008) leads to BM stem cell reservoir replenishment, we measured BM HSPC levels along 24 hr ( Figure 1A ). We À LSK cell increments at 7 a.m.
and 7 p.m. (Figures 1E and 1F) preceding the HSPC peaks suggested that ROS elevation promotes their proliferation, inducing small HSPC subsets to cycle at 11 a.m. and 11 p.m. Mouse treatment with a ROS scavenger, N-acetyl cysteine (NAC), following initiation or termination of light led to reduced BM CD34 À LSK cell levels (Figures 1G and 1H) . We looked for factors that may elevate ROS levels. BM-resident HSPCs are regulated by inflammatory cytokines activating stress signals (Schuettpelz and Link, 2013; Trumpp et al., 2010) , among them TNF, which is also implicated in their activation (Cabezas-Wallscheid et al., 2017) . Mice treated with TNF to activate their HSPCs had elevated levels of ROS high /CD34 À LSK cells in the BM 4 hr later (Figures 1I and 1J) . Tracking BM TNF levels revealed two daily peaks, a higher one at 7 a.m. and a modest one at 7 p.m. (Figure 1K ), suggesting light-and dark-induced TNF involvement in BM HSPC regulation.
TNF Bursts Are Essential for BM HSPC Peaks
We tested the levels of the TNF-converting enzyme (TACE), which cleaves TNF from the plasma membrane of cells to its active form (Black et al., 1997) . TACE levels fluctuated both on BM HSPCs ( Figure 2A ) and on monocytes ( Figure S1A ). We found two peaks of TACE elevations specific for HSPC, corresponding to the 7 a.m. and 7 p.m. BM TNF peaks. Next we administered a TACE inhibitor (Sagi et al., 2015) to mice after initiation or termination of light and found reduced BM HSPC peaks (Figures 2B and 2C) . We further utilized a genetic model of TNF knockout (KO) mice and also treated wild-type (WT) mice with a TNF antagonist. No oscillations were observed in BM colony forming unit cells (CFU-C) of TNF KO mice compared with WT mice ( Figure 2D ). Moreover, both peaks of BM HSPC documented in WT mice at 11 a.m. and 11 p.m. were decreased in these mice . Antagonizing TNF during the morning revealed higher levels of BM HSPCs in their quiescent phase of the cell cycle at 11 a.m. (Figure S1B ). Interestingly, TNF deficiency also prevented the daily ROS peaks in BM HSPCs ( Figure 2I ), suggesting that TNF bursts are crucial for HSPC ROS oscillations. We established chimeric mice with WT hematopoietic cells transplanted into TNF KO mice and vice versa and found that the hematopoietic but not stromal compartment is responsible for TNF secretion and HSPC ROS regulation at 7 a.m. (Figures 2J and 2K) . TNF activates nuclear factor kB (NF-kB) signaling cascades (Morgan and Liu, 2011) , which regulate HSPCs; in particular, p65 (canonical pathway) is essential for HSC function (Stein and Baldwin, 2013) , whereas RelB (noncanonical pathway) regulates HSC development (Zhao et al., 2012) . We found higher levels of phosphorylated p65 and RelB molecules in HSPCs at 7 a.m. compared with 7 p.m. (Figures  2L and 2M ). Utilizing TNF KO mice or TNF antagonist treatment led to reduced p65 and RelB phosphorylation at 7 a.m. and 7 p.m. in BM HSPCs (Figures 2L and 2M) . Altogether, this suggests that TNF signaling is important for the two major BM HSPC peaks.
Light and Darkness Onset Induce Transient TNF Bursts via NE Upregulation To determine whether light and dark signals modulate TNF levels, we scored cytokine concentration. Profound transient changes in TNF levels were observed 1 hr after transferring mice from light to darkness in both BM and plasma, which were back to basal levels following 2 hr ( Figures 3A and S1C) . A similar trend was documented upon transferring mice from darkness to light ( Figures 3B and S1D ). Because NE signaling regulates BM HSPC egress at 11 a.m. (Mé ndez-Ferrer et al., 2008) , we monitored its levels and found that BM NE peaked at 7 a.m. and, to a lower extent, at 7 p.m., similar to the TNF bursts ( Figures 3C and S1E ). Blockage of b2-or b3-adrenoreceptors (b2ARs or b3ARs) following light initiation showed that a b2AR but not b3AR antagonist reduced TACE levels on BM HSPCs and monocytes, decreasing TNF levels at 7 a.m. ( Figures  3D-3G and S1F). Accordingly, mice deficient in b2AR (b2AR À/À ) or both b2AR and b3AR (b2AR À/À /b3AR À/À ), but not b3AR only, had reduced BM TNF levels at 7 a.m. (Figure 3H ). Moreover, inhibition of b2AR reduced TACE levels on BM HSPCs and monocytes and also decreased TNF levels at 7 p.m. ( Figures  3I-3L ). Both NE and TNF induce ROS elevation in cells. Therefore, we treated mice with NAC to scavenge ROS following initiation or termination of light and found reduced TACE levels on BM HSPCs and monocytes as well as decreased BM TNF levels at 7 a.m. and 7 p.m. . Further studying the cross-talk between NE and TNF revealed higher basal NE levels in TNF KO mice and WT mice treated with the TNF antagonist ( Figure S1G ), suggesting a negative feedback loop. We administered NE at an HSPC-mobilizing dose (Dar et al., 2011) and found that TNF KO mice were unable to mobilize HSPCs ( Figure S1I ) despite high sensitivity to PBS injections, which elevated circulating white blood cells (WBCs) ( Figure S1H ). These results suggest that, upon light induction or termination, stress reactions activate the sympathetic nervous system to increase TACE on BM HSPCs and monocytes via NE and b2AR, leading to BM TNF elevations, which induce both HSPC peaks.
The Morning HSPC Peak Regulates Differentiation and Egress, whereas the Night Peak Regulates Retention To learn the two HSPC peaks function, we examined the shortand long-term (LT) HSPC repopulation potential. BM cells harvested at 11 a.m. and 11 p.m. were transplanted in competitive repopulation assays ( Figure 4A ). Despite high BM HSPC content at 11 a.m. (Figures 1B and 1D ), these cells had inferior short-and long-term repopulation activity compared with 11 p.m. BM HSPCs ( Figures 4B and 4C ). Importantly primitive BM CD150
Because LT-HSC fluctuations cannot be explained by the limited proliferation of CD34
-LSK cells, we tested whether light and dark cues change their phenotype and function by dynamic changes in cell surface antigen expression. We found augmented CD150 high levels of expression on CD34 À LSK cells at 11 p.m. compared with 11 a.m. ( Figure S2C ). Next, we prevented light induction at 6 a.m., keeping mice under extended dark conditions up to 11 a.m., which maintained higher (P) Levels of BM Evans Blue dye absorbance per femur at 620 nm in mice (n = 4). Error bars, mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; Student's two-tailed unpaired t test (B, C, F, G, and P) and one-way ANOVA with Tukey's post hoc test (E, I-M, and O). See also Figure S2 . (CLPs), neutrophils, monocytes, and lymphocytes. In contrast, at 11 p.m., we found no elevations in these immature and mature populations ( Figures 4H-4M , respectively). Because HSPC differentiation and egress are linked to ROS elevation (Golan et al., 2012; Ludin et al., 2014; Suda et al., 2011) , we measured the levels of circulating HSPCs, which indicate their egress from the BM. Egress was high during the morning HSPC peak (11 a.m.) and low at night ( Figures 4N and 4O ), corroborating previous reports (Mé ndez-Ferrer et al., 2008) . Moreover, mature leukocyte egress was also increased during the morning HSPC peak ( Figures S2G and S2H ). More permeable BM sinusoidal blood vessels are the major site for HSPC trafficking from and to the BM (Itkin et al., 2016) . We measured BM vascular permeability and found higher permeability at 11 a.m., in line with the extended cell egress ( Figure 4P ). Another regulator of lymphocyte and HSPC egress and mobilization is the bio-active lipid S1P (Pappu et al., 2007; Golan et al., 2012; Juarez et al., 2012; Ratajczak et al., 2010) . Measuring S1P levels in the plasma revealed higher levels of S1P during the morning compared with night ( Figure S2I ). In accordance, higher S1P levels at night were measured in the BM ( Figure S2J ), further suggesting BM HSPC retention. In summary, during the 11 a.m. peak, HSPCs are primed to a state of high differentiation and egress, imposing a lower repopulation potential. In contrast, during the 11 p.m. peak, HSPCs are primed to a state of retention with low differentiation and high BM reservoir replenishment, including LT-HSCs, imposing a high repopulation potential. À LSK levels ( Figure 5G ). Next we tested CMP and CLP levels and HSPC egress at 11 a.m. in TNF KO and WT mice treated with the TNF antagonist. Both mouse models had reduced BM CMP and CLP levels and decreased HSPC egress to the circulation (Figures 5H-5K and S3H, respectively). When we treated mice with NE at light termination ( Figure 5L ), it induced ROS elevation ( Figures 5M, 5N , and S3I). Moreover, NE injection ( Figure 5O ) enhanced the levels of BM CMPs (Figures 5P and S3J) and CLPs ( Figures 5Q and S3K ), BM vascular permeability (Figures 5R and S3L) , and HSPC egress to the circulation ( Figures 5S, S3M , and S3N). These results reveal that light-induced NE elevation in the BM leads to increased TACE expression, TNF shedding via the b2AR on BM leukocytes, induction of HSPC differentiation and egress and increased BM vascular permeability via the b3AR.
Melatonin Retains Undifferentiated HSPCs in the BM during the Night Peak
Melatonin is present in the BM and is also produced by BM cells (Carrillo-Vico et al., 2013; Conti et al., 2000; Tan et al., 1999) . By measuring melatonin levels in plasma and BM fluids, we found the highest levels at night (11 p.m.) (Figures 6A and 6B) . TNF inhibits melatonin production in the pineal gland (Fernandes et al., 2006) but induces its production by macrophages (Muxel et al., 2012) . Interestingly, TNF KO mice or mice treated with its antagonist had lower BM melatonin levels at 11 p.m. (Figure 6C) . Injection of the melatonin antagonist luzindole (Figure 6D) at night induced HSPC differentiation (Figures 6E and 6F and S4A and S4B) and increased BM vascular permeability ( Figure 6G ) and HSPC egress to the circulation (Figures 6H and S4C) . Similarly, luzindole induced the release of neutrophils and monocytes (Figures S4D and S4E) . Melatonin injection in the morning ( Figure 6I ) reduced ROS levels in BM CD34 À LSK cells (Figures 6J and 6K) and their CMP and CLP differentiation (Figures 6L and 6M) . Melatonin administration also reduced BM vascular permeability ( Figure 6N ) and HSPC egress to the circulation (Figures 6O and S4F) at 11 a.m. Because we found elevated LT-HSC function during nocturnal melatonin secretion ( Figure 4C ), we added a signaling lymphocyte activation molecule (SLAM) cell marker and examined whether a more primitive phenotype of Flt3 À
CD34
À SLAM)/LSK is also elevated at night.
Indeed, we saw increased BM Flt3 These results reveal similar trends for mice and humans with regards to melatonin regulation of HSPCs. Of note, C57BL/6 mice have lower melatonin production by the pineal gland but high melatonin levels in the BM (Conti et al., 2000) . To exclude strain-specific phenotypes, we tested C3H/HeN mice with normal melatonin levels and documented similar patterns of HSPC ROS levels and BM HSPC peaks, with elevated LT-HSC levels at 11 p.m. with increased differentiation and egress at 11 a.m. (Figures S5A-S5G ). Both MT1 and MT2 melatonin receptors are expressed on BM CD34 -LSK HSPCs ( Figure 6S ). Upon binding of melatonin to its receptors, several molecular pathways can be activated or repressed, among them Akt (Blask et al., 2014) . We treated BM cells in vitro with melatonin for (O-S) Schematic illustration of the NE double injection protocol related to (P)-(S) (O), Numbers of BM CMP (P, n = 5) or CLP (Q, n = 6) cells per femur, Evans Blue dye absorbance per femur at 620 nm (R, n = 4) and circulating LSK cells per milliliter of blood (S, n = 8) in NE-treated mice at night. Error bars, mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001; Student's two-tailed unpaired t test (B-G and N-S) and one-way ANOVA with Tukey's post hoc test (I-K). See also Figure S3 . and found reduced ROS levels in BM HSPCs ( Figure 6U ). These results suggest that melatonin can directly regulate BM HSPC retention in a low metabolic state during the night peak.
Melatonin Elevates BM COX-2/aSMA Macrophages Rare COX-2/a smooth muscle actin (aSMA) macrophages preserve BM HSPCs by reducing their ROS levels (Ludin et al., 2012) . We detected the highest levels of BM aSMA macrophages at 11 p.m. (Figures 7A and S5G ). Importantly, their COX-2 expression was also enhanced ( Figure 7B ), revealing their activated state. These cells express MT1 and MT2 melatonin receptors ( Figures 7C, S6A , and S6B). Enforced morning melatonin elevation ( Figure 7D ) upregulated BM aSMA macrophage levels (Figure 7E) . Interestingly, melatonin reduced the aSMA macrophage G 0 phase of the cell cycle ( Figure 7F ) and increased their ROS levels ( Figure 7G ). Moreover, melatonin also decreased aSMA macrophage egress to the circulation ( Figure S6C ). Accordingly, melatonin receptors inhibition by luzindole ( Figure 7H ) reduced BM aSMA macrophage levels at 11 p.m. (Figure 7I ), increased their G 0 cell cycle phase ( Figure 7J ), and reduced their ROS levels ( Figure 7K ). Melatonin treatment did not increase COX-2 expression ( Figure S6D ). Because S1P increases COX-2 expression in smooth muscle cells (Hsieh et al., 2006) , and BM S1P levels increase during the night ( Figure S2H ), our data suggest that the augmented S1P levels in the BM induce nocturnal COX-2 elevation. Next we inhibited COX-2 activity in mice by using a specific inhibitor at night to abolish the regulatory effect of this enzyme ( Figure 7L ), which did not reduce the population of BM COX-2/ aSMA macrophages ( Figure S6E ). This treatment enhanced HSPC CMP and CLP differentiation ( Figures 7M and 7N , respectively, and S6F and S6G) and their egress to the circulation (Figures 7O, S6H, and S6I Figures 7R and S6K ). Finally, we utilized CX 3 CR1/ diphtheria toxin receptor (DTR) mice, in which we ablated CX 3 CR1 + monocytes and macrophages (Diehl et al., 2013) . Because COX-2/aSMA macrophages express this receptor (Ludin et al., 2012) , their levels were decreased upon administration of diphtheria toxin to these mice ( Figure 7S ). Interestingly, we also found reduced levels of primitive CD150 + CD34
À LSK LT-HSC levels at 11 p.m. in these mice (Figures 7T and S6L) . Our data reveal how melatonin directly and indirectly, via aSMA macrophages, maintains undifferentiated BM HSPCs, including their LT-HSC function, during the night.
DISCUSSION
In this study, we identified daily fluctuations driven by light and dark signals, which regulate BM HSPCs. Light induction initiates sympathetic signals, inducing egress of BM HSPCs, including LT-HSCs (Casanova-Acebes et al., 2013; Mé ndez-Ferrer et al., 2008) . In the morning, we found enhanced BM HSPC proliferation and differentiation, including CLP and CMP elevations prior to their egress. Consequently, the BM requires daily replenishment with new immature and maturing cells to allow continuous homeostatic balance between ongoing demands of mature blood cell production while maintaining the reservoir of undifferentiated stem and progenitor cells. Thus, our results reveal, during the day, replenishment of the circulation with immature and mature leukocytes, whereas at night, the BM pool of stem and progenitor cells is replenished.
We identified two major BM HSPC peaks at 11 a.m. and 11 p.m., in line with a previous report (Ieyasu et al., 2014) . Our data suggest that BM HSPCs are metabolically programmed by daylight NE-induced signals for their differentiation and egress, accompanied by reduced repopulation potential. These BM HSPCs are metabolically reprogrammed at night by dark signals to reacquire their undifferentiated state, accompanied by elevated repopulation potential. The night HSPC state is a result of limited HSPC proliferation but more due to dynamic changes in cell surface antigen expression and metabolic state induced by melatonin. Surface CXCR4 fluctuates between day and night (Mé ndez-Ferrer et al., 2008) , and surface LT-HSC endothelial protein C receptor (EPCR) is shed by TACE and later re-expressed in the BM (Gur-Cohen et al., 2015) . Overall, lightinduced HSPC migration and development versus dark-induced optimal LT-HSC function recovery on a daily basis suggest tight regulation of the HSC state and readiness to rapidly act upon demand. Thus, homeostatic regulation maintains and ''trains'' HSCs for emergency acute stress situations when their function is critical for rapid production of mature blood and immune cells while maintaining the stem cell reservoir to prevent hematology failure.
HSPCs, including LT-HSCs, functionally express TNF receptors and are regulated by TNF released during infection onset (King and Goodell, 2011; Trumpp et al., 2010) . In line with this, TNF promotes BM regeneration (Bowers et al., 2018) . We identified two BM TNF daily bursts following light initiation and termination. Restricting TNF genetically or pharmacologically abolished the daily peaks, attributing a pivotal role to TNF in BM HSPC regulation. TNF bursts decode the environmental information of light on/off transitions, which may serve as a transient physiological stress, preparing BM HSPCs for their sequential activation. Light and dark induction elevated BM NE, which acts directly on leukocytes to increase TACE expression, leading to TNF cleavage.
Daylight raised NE, reduced BM CXCL12, and induced CXCR4 + HSPC egress (Lucas et al., 2008; Mé ndez-Ferrer et al., 2008) . Antagonizing either b3AR or TNF signaling inhibited the morning peak and reduced vascular permeability, HSPC differentiation, and egress. NE treatment induced rapid murine HSPC mobilization (Dar et al., 2011) and human peripheral blood myeloid cell differentiation, associated with ROS production (Liu et al., 2015) . Although ROS are rapidly elevated by the NE and TNF 7 a.m. peak, the outcome of this process is evident only a few hours later in terms of differentiation and egress. Intriguingly, the high 7 a.m. NE and TNF bursts facilitated HSPC differentiation and egress, whereas their lower 7 p.m. bursts induced limited HSPC proliferation without differentiation and egress. These dual effects suggest multifactorial regulation. The major night peak is predominantly driven by elevation of BM melatonin, which, together with COX-2/aSMA macrophages and reduced endothelial cell permeability, inhibited HSPC differentiation and egress. In support of our study, CD8/T cell receptor (TCR À ) cells enhanced HSPC engraftment by TNF-dependent regulation (Rezzoug et al., 2008) . Melatonin protected circulating human HSPCs from chemotherapy via ROS downregulation (Carrillo-Vico et al., 2013) and human BM stromal cells from toxicity (Mehrzadi et al., 2017) .
COX-2/aSMA macrophages support BM HSPC retention by lowering their ROS levels (Ludin et al., 2012) . These cells functionally express melatonin receptors and peak at night in response to melatonin. Antagonizing melatonin signaling or inhibiting COX-2 at night turned the BM to a morning-like phenotype. Interestingly, partial deletion of COX-2 high /aSMA macrophages from the BM reduced LT-HSC levels, further demonstrating the importance of these cells in HSPC BM maintenance.
Our study demonstrates a tightly synchronized balance of BM NE, TNF, COX-2, and melatonin to maintain mature leukocyte homeostasis. Basal inflammatory signals are required for steady-state HSC function (King and Goodell, 2011). Of interest is that lipopolysaccharide (LPS) induced HSPC proliferation directly via their TLR4 following a short stimulation. However, longer exposure impaired HSC competitive self-renewal and repopulation (Takizawa et al., 2017) , demonstrating the need for robust short pulses of pro-inflammatory signals rather than chronic stimulations, which impair stem cell function.
We found dynamic oscillations of the BM homeostatic milieu of cytokines, hormones, and neurotransmitters, which are crucial for maintaining the dual activity of HSPCs: replenishing the blood with new mature cells with a finite lifespan on demand while maintaining the BM reservoir of undifferentiated stem and progenitor cells.
Our preliminary results reveal similar effects of melatonin on human HSPCs, including LT-HSCs. These data suggest that the time of BM HSPC harvest and transplantation may affect engraftment and repopulation efficiency in clinical BM transplantation. These results also suggest that manipulations with light and dark cues, melatonin, NE, COX-2, and TNF could improve clinical stem cell transplantation protocols.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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STAR+METHODS KEY RESOURCES TABLE
Xenogeneic models and human data
Animal experiments were done in accordance to the institutional guidelines approved by the University Health Network animal care committee. NSG female mice (NOD.Cg PrkdcscidIl2rgtm1Wjl /SzJ; Jackson Laboratory) or NSG-SGM3 female mice (NOD-scid IL2Rgnull-3/GM/SF; Jackson Laboratory) were sub-lethally irradiated with 250 Rad 24 hours before intrafemoral injection with 100,000 Lin -human cord blood (CB) cells. Xenografts were treated at 4 weeks post-transplantation with vehicle control (EtOH) or melatonin (0.75mg/kg freshly dissolved in vehicle from Sigma) by peritoneal injection at the start of light at 6AM and then euthanized at 10AM for human chimerism analysis. The injected femur and non-injected femur were collected and crushed in Iscove's modified Dulbecco's medium and human chimerism and HSPC populations were assessed as described in the flow cytometry section below.
METHOD DETAILS
In vivo treatments
For circadian studies, mice were sacrificed 1h (7AM) and 5h (11AM) after light initiation at 6AM or 1h (6PM) and 5h (11PM) after light termination at 6PM. TNF was purchased from PeproTech (cat # 300-01A, Human recombinant TNF) and was injected intraperitoneally at 5mg/mouse for 4h before cells were harvested at 11PM. TACE monomeric prodomain inhibitor was developed and produced as previously described (Sagi et al., 2015) . The TACE inhibitor was used in vivo and administrated intravenously at 25 mg/mouse at 6AM to inhibit BM HSPC peak at 11AM or at 12.5 mg/mouse 6PM to inhibit BM HSPC peak at 11PM. TNF antagonist was purchased from Calbiochem (cat #654255) and was injected intraperitoneally at 10mg/mouse twice, at 6AM and 9AM, to inhibit the morning HSPC peak at 11AM or at 5mg/mouse once at 6PM to inhibit the night HSPC peak at 11PM. N-Acetyl Cystein (NAC) was purchased from Sigma (cat # A8199) and was injected intraperitoneally at 25mg/kg at 6AM to monitor TACE and TNF levels at 7AM or to inhibit 11AM BM HSPC peak. NAC was administered at 10mg/kg at 6PM to monitor TACE and TNF levels at 7PM or to inhibit 11PM BM HSPC peak.
b3AR antagonist (SR58894A) was purchased from Sigma (cat # SML0581) and was injected intraperitoneally at 10mg/kg twice, at 6AM and 9AM, to inhibit the morning HSPC peak at 11AM. b3 antagonist was also injected intraperitoneally at 20mg/kg at 5AM to monitor TACE and TNF levels at 7AM. b2AR antagonist (ICI) was purchased from Sigma (cat # I127) and was injected intraperitoneally at 5mg/kg at 6AM or at 6PM to monitor TACE and TNF levels at 7AM or 7PM respectively. NE was purchased from Sigma (cat # A9512) and was injected intraperitoneally at 10mg/kg twice, at 6PM and 9PM, to modify the night HSPC peak at 11PM. NE was also injected at 2PM (10mg/kg) to induce mobilization in WT and TNF KO mice at 3PM. Luzindole was purchased from Sigma (cat #L2407) and was injected intraperitoneally at 2.5mg/kg once at 6PM to inhibit the night HSPC peak at 11PM. Melatonin was purchased from Sigma (cat #M5250) and was injected intraperitoneally at 0.75mg/kg once at 6AM to modify the morning HSPC peak at 11AM. COX-2 inhibitor (NS398) was purchased from Sigma (cat #N194) and was injected intraperitoneally at 10mg/kg twice at 6PM and 9PM to inhibit the night HSPC peak at 11PM.
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Flow cytometry
Cell populations were analyzed with a MacsQuant VYB instrument (Miltenyi, Bergisch Gladbach, Germany) or with a FACS LSRII (BD Biosciences) with FACSDiva software. Data were analyzed with MacsQuant or FlowJo respectively. Flushed bone marrow cells were stained for 30 minutes at 4 C in flow cytometry buffer (PBS, 10% FCS and 0.02% azide). For antigens that require intracellular staining (aSMA macrophages, Ki67, COX-2, MT1 and MT2 melatonin receptors, phosphorylated RelB or p65, phosphorylated Akt), cell surface staining was followed by cell fixation and permeabilization with the Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer's instructions. For LSK (Lin -Sca-1 + c-Kit + ) staining, we used a lineage cocktail of either FITC-conjugated antibodies to CD4 (GK1.5), CD8 (53-6.7), B220 (RA3-6B2), CD11b (M1/70), Gr-1 (RB6-8C5) and Ter119 (TER-119) (all from Biolegend) or a biotinylated lineage cocktail (Miltenyi), together with anti Sca-1-PE (D7) or Sca-1-PE-Cy7 (D7) and anti c-Kit-APC (2B8) (all from Biolegend). As secondary conjugated antibody we used Streptavidin-PE-Cy7 (Biolegend). , 2018) were determined by staining with a lineage cocktail of FITC-conjugated antibodies as described above was used (all from Biolegend) together with anti Sca-1-PE-Cy7 (D7, BioLegend), anti c-Kit-APC (2B8, Biolegend) and anti-CD127 (IL7Ra)-PE-Cy7 (A7R34, BioLegend). Neutrophils (CD11b + Ly6G + ) and monocytes (CD11b + Ly6C + ) were identified by staining with anti-CD11b-FITC (M1/70, BioLegend) and anti-Ly6G-APC (1A8, biogems) or anti-Ly6C-PE-Cy7 (HK1.4, BioLegend). For lymphocyte detection, rat anti mouse CD45R/B220-PE (RA3-6B2, BD Biosciences) was used. TACE levels were detected by anti-TACE (ADAM17) polyclonal antibody (ab39163, Abcam). Levels of cells in G 0 state were determined by staining for cell surface markers of CD34 -LSK as described above or aSMA macrophages markers as described below following fixation and permeabilization and staining with mouse anti-human Ki67-FITC set (556026, BD Biosciences). Detection of aSMA macrophages (CD11b + aSMA + ) was done by staining for cell surface marker with anti-CD11b-APC (M1/70, eBioscience) following fixation and permeabilization. Then anti-aSMA-FITC monoclonal antibody (1A4, Sigma) was used. Detection of either COX-2 or MT1/MT2 receptors in aSMA macrophages was done after staining for these cells as described above and further using anti-COX-2-unconjugated polyclonal antibody (aa570-598, Cayman chemical company) or anti-MT1-unconjugated polyclonal antibody (Imuny) or anti-MT2 polyclonal antibody (Imuny). Detection of MT1/MT2 receptors in CD34/LSK cells was done after staining for these cells as described above and further using anti-MT1-unconjugated polyclonal antibody (Imuny) or anti-MT2 polyclonal antibody (Imuny). For phosphorylated antibody detection, the bones were maintained on ice followed by flushing and staining on ice. Detection of phosphorylated RelB/p65/Akt were done by staining for cell surface marker for CD34 -LSK followed by fixation and permeabilization. Then anti-phosphorylated (Ser552) RelB-PE monoclonal antibody (D41B9, Cell Signaling) or anti-phosphorylated (Ser536) p65-PE monoclonal antibody (93H1, Cell Signaling) or anti-phosphorylated (Thr308) Akt polyclonal antibody (9275S, Cell Signaling) were used. For Lineage (Lin -) separation a biotinylated lineage cocktail (Miltenyi) was first used followed by anti-biotin microbeads (Miltenyi) according to manufacturer's instructions.
Human HSPC populations were assessed with the following antibodies by flow cytometry on a BD Celesta (from BD Biosciences): FITC-anti-CD45RA, PE-anti-CD90, PE-Dazzle-anti-CD38, BV650-anti-CD49f, APC-anti-CD71, APC-cy7-anti-CD34, AF700-anti-CD10, AF700-anti-CD7, V500-anti-CD45, BV711-anti-CD19 and BV421-anti-CD33. We identified human LT-HSC (CD34 TNF ELISA Method #1: refers to all TNF measurements except for Figure 3H TNF ELISA was performed by using a mouse TNF ELISA MAX TM Deluxe kit (BioLegend, 430904) according to manufacturer's instructions. Total protein content in BM fluids was quantified by Bradford assay and TNF concentration in the BM fluids was normalized per protein content. Values were expressed as pg/mg protein for BM samples and as pg/ml for plasma samples. The assay has a detection limit of 4pg/ml. The 0pg/ml threshold was set according to plasma TNF KO samples that showed 0pg/ml. However in the plasma we obtain values that are below the ELISA kit sensitivity value and therefore are only suggestive. The 0pg/mg protein threshold for the BM measurements was set according to BM supernatant TNF KO samples. Of note, in the BM there was a false positive background of 3.22pg/mg protein in TNF KO samples thus this value was subtracted from all the TNF levels of WT samples and was set as the point of 0pg/mg protein in all the graphs of BM TNF levels. Method #2: refers only to Figure 3H TNF ELISA was performed by using the MILLIPLEX MAP Mouse Cytokine/Chemokine Magnetic Bead Panel -Immunology Multiplex Assay (MCYTOMAG-70K, Merck), according to manufacturer's instructions. BM extracellular fluid samples were collected at 7AM and TNF was measured. TNF concentration (pg/ml) was normalized to protein concentration (mg/ml) measured with BCA Protein Assay Kit (Thermo Scientific; #23227). Due to difference in the TNF levels obtain by these two methods, TNF levels in Figure 3H are expressed as fold change.
Melatonin ELISA
The content of melatonin in plasma and BM fluids was measured through enzyme-linked immunosorbent assays (Melatonin ELISA; IBL, Hamburg, Germany) according to the manufacturer's instructions. Values were expressed as ng/mL and the assay has a detection limit of 3pg/mL.
Competitive repopulation assay BM cells from C57BL/6 (CD45.2) mice harvested at 11AM or 11PM were transplanted into lethally irradiated (950 cGy) B6.SJL (CD45.1) congenic mice (2 3 10 5 donor cells collected at the same time from the standard room (11AM) or the inverse light/dark cycles room (11PM) with 4 3 10 5 host cells collected only from the standard room (11AM) were transplanted at 3PM in the standard room). BM transplantation was performed 24 h after irradiation. Mice were killed 1 month or 4 months later and the levels of donor chimerism were determined by flow cytometry using rat anti-mouse CD45.2 (BioLegend) and CD45.1 (eBioscience). In the experiments with b3-antagonist, mice were treated with the antagonist at 6AM and 9AM and the BM cells were harvested at 11AM. For the short-term repopulation following melatonin treatment, donor C57BL/6 mice were treated with melatonin at 6AM and sacrificed at 11AM. Donor cells were transplanted into B6.SJL congenic mice (full dose (x) -2 3 10 5 donor cells collected at the same time with 4 3 10 5 host cells or half dose (1/2x) -1 3 10 5 donor cells collected at the same time with 4 3 10 5 host cells).
Chimera mice establishment
Recipient TNF KO or WT mice were subjected to irradiation (950 cGY) 16-20h before transplantation. BM cells (10 3 10 6 donor cells) from WT or TNF KO mice was harvested and transplanted as following: WT into TNF KO and TNF KO into WT recipients. Four weeks after transplantation the experiments were conducted by killing the mice at 7AM and comparing their TNF and ROS HSPC levels.
Colony-forming assay (CFU-C) BM mononuclear (BM-MNC) cells were isolated by Ficoll separation and were seeded (15x10 3 cells/ml) in CFU-C semisolid medium supplemented with EPO, IL-3, GM-CSF and SCF as described (Kollet et al., 2006) . CFU-C were scored 7 days after plating and presented as CFU-C per number of seeded cells.
In vivo Evans Blue dye BM penetration assay BM vascular endothelial barrier function was assessed using the Evans Blue Dye (EBD) assay. Evans Blue (Sigma-Aldrich) dissolved with PBS was injected i.v. to mice. For the WT 11AM and 11PM as well as for NE, Luzindole or melatonin treated mice we injected 10mg/ml Evans Blue Dye 5h before mice were euthanized. For b3-antagonist treated mice we injected 20mg/ml Evans Blue Dye 2h before mice were euthanized. In each experiment, a non-injected mouse was used for control blank measurements. Subsequently, mice were perfused with PBS via the left ventricle to remove intravascular dye. Femurs were removed and formamide was used for bone flushing, crushing and chopping. EBD was extracted in formamide by incubation and shaking of flushed and crushed fractions, overnight at 60 C. Next, we performed 30 min centrifugation at 2,000g, EBD in BM supernatants was quantitated by spectrophotometric analysis at 620 nm. (as described in the flow cytometry section). Lin À cells (5 3 10 5 ) were cultured in 24-well plates (Costar) with or without 10nM melatonin for 1h. The cells were taken and stained for ROS/CD34 -LSK. Cultures were incubated for the appropriate time at 37 C in humidified chambers containing 5% CO 2 .
NE measurements by LC/MS Method #1: refers to all NE measurements except for Figure S1G Samples preparation. BM cells were flushed with PBS and the cells were incubated for 45min at 37 C, 5% CO 2 . The condition medium of these cells was collected and centrifuged at 4 C for 5 minutes. Plasma was also collected and centrifuged at 4 C for 5 minutes. Then 50mL of each sample was mixed with 10 mL of metabisulfite (stock concentration 50 mM) for preservation. Later standards (NE and deuterated noradrenaline) and 200 mL of pure acetonitrile were added. After vortex and centrifugation at 4 C samples were transferred into fresh tubes. Sodium chloride was added and after centrifugation supernatants were collected. Then 25 mL of tetraborate buffer solution (stock: 0.2M) and 7 mL of 100% Benzoil chloride were added with a subsequent very long and careful vortexing for derivatization. Next, the samples were incubated for 10 minutes and sodium chloride was added to separate water phase from organic phase, and after intensive mixing, short incubation and short spin 100 mL of the upper phase was transferred into the bottles. Finally 25 mL of pure methanol was added. To remove NA from control samples, we performed 48 hours long UV radiation with meanwhile stirring. Measurements all the measurements were performed on high resolution ESI-QqTOF system (TripleTOF 5600 + , DuoSpray Ion Source, external ion calibration; AB Sciex) after chromatographic separation (Nexera XR, Shimadzu). The spectrometer was set to MS/MSHR positive mode, spectra in range of 50-650 Da were collected in accumulation time of 150 ms for product ion 482.2 (NE) and 488.2 (NE-d6), at declastering potential (DP) of 60 for both compounds, collision energy (CE) of 15 for NE and of 17 for NE-d6. Ion source parameters (ESI): Ion source gas (GS1) -40, ion source gas (GS2) -50, curtain gas (CUR) -35, source temperature 6000C, ion spray voltage floating -5500. Chromatographic conditions: mobile phase in gradient of water 0.1% formic acid (A) and acetonitrile 0.1% formic acid (B)-0-0.5 min 95% A, 6 min -100% B, 10 min 100% B, 10.1 min -95% A, 12 min -95% A. Chromolith Performance RP-18e 100-2 mm column (Merck) with guard cartridge RP-18e 5-2 mm at 250C.Quantitative analysis we made on MultiQuant (AB Sciex) software, peaks were calculated for product ion signals in range of 464.12-464.17 Da (NE) and 470.15-470.21 (NE-d6). Method #2: refers only to Figure S1G Aqueous solution (20mL of 1mg/mL) of d 6 -norepinephrine (C.D.N. Isotopes, Canada) was added as internal standard to 300mL of the sample medium. The mix was diluted with 3mL of acetonitrile, followed by centrifugation (21,000 gx15min). The collected supernatant was evaporated then re-dissolved in 0.1% formic acid (50mL). Derivatization of amine containing metabolites was performed using Aqc reagent, followed by analysis of norepinephrine and d 6 -norepinephrine by liquid chromatography-tandem mass spectrometry as described (Boughton et al., 2011; Wolf et al., 2017) .
S1P measurement by RP-HPLC
The measurement of sphingosine-1-phosphate was performed by reversed-phase high-performance liquid chromatography (RP-HPLC) with Hewlett-Packard Series 1200 liquid chromatograph. Internal C17S1P standard (Avanti Polar Lipids) and samples were thawed at room temperature. For 100 mL sample volume, 30 mL of the C17S1P internal standard (diluted in 10 mM K 2 HPO 4 mixture of methanol (MetOH), pH 7.2) was added. Mixture of standards was prepared as following: 30 mL of internal standard C17S1P (diluted with a mixture of K 2 HPO 4 :MetOH, pH 7.2) and 30 mL of internal standard C18S1P (diluted in a mixture of K2HPO4:MetOH, pH 7.2). The samples were mixed and supplemented with 1 M NaCl solution up to 1mL volume. After stirring, 1 mL of methanol and 300 mL of concentrated hydrochloric acid were added. After intensive mixing 2 mL of chloroform was added, stirred (20 min, 900 rpm), and centrifuged (3 min, 3500 rpm, 20 C). We transferred separated lower organic phase into a new tube and the upper phase was reextracted and the lower organic phase was combined with the previously collected one and dried in a vacuum centrifuge for about 45 min at 45 C. Immediately before the measurements, the dried extracts were dissolved in 130 mL of methanol and 20 mL of OPA mixture. OPA mixture was prepared as following: 5 mg of o-phthalic dialdehyde, 100 mL of methanol, 5 mL of mercaptoethanol and 5 mL of boric acid at pH 10.5. At the same time we prepared a mixture containing 30 m of internal standard C17S1P and 30 mL of internal standard C18S1P, to which we added 940 mL of a mixture of K 2 HPO 4 :MetOH, pH 7.2. 600 mL was transferred to a new tube and 75 mL of OPA was added. Samples with OPA were incubated in the dark at room temperature, 20 min and then centrifuged (10 min, 6000 rpm, 20 C). We obtained clear supernatant which was transferred to a fresh collecting tube, where we added 20 mL of 10 mM K 2 HPO 4 buffer, and after incubation (10 min, +4 C) and centrifugation (5 min, 6000 rpm, 20 C) the supernatant was transferred into a vial and analyzed. Data were analyzed with HP Chemstation software (Agilent, USA). Separation in the reversed phase column was carried out on a Cosmosil 5 mm C18-ARII column (150 3 4,6) with a 5 mm C18-ARII (10 3 4.6) pre-column (Waters). Column temperature was 25 C. The isocratic method with mobile phase consisting of 10 mM K 2 HPO 4 (pH 5.5) and methanol (15:85; v/v) was used. The flow rate was 1 mL/min 50 mL samples were injected every 30 min. The wavelength for the detection of S1P derivatives was 340 nm for the excitation and 455 nm for emission. The calculation of S1P concentration was based on the peak area of the internal standard C17-S1P.
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QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were conducted with Prism 6.0c version (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ''ns'' represents non significance). All data are expressed as mean ± standard error (SEM) and all n numbers represent biological repeats. Unless indicated otherwise in figure legends, a Student's two-tailed unpaired t test was used to determine the significance of the difference between means of two groups. One-way ANOVA was used to compare means among three or more independent groups. Bonferroni or Tukey post hoc tests were used to compare all pairs of treatment groups when the overall p value was < 0.05. Animals were randomly assigned to treatment groups.
DATA AND SOFTWARE AVAILABILITY
Download links for software used in this study are provided in the Key Resources Table. Cell Stem Cell 23, 1-14.e1-e7, October 4, 2018 e7 + CD34 -LSK cells following TNF antagonist administration. (G-H) Numbers of circulating neutrophils (E, n = 7) and monocytes (F, n = 6) per ml of blood. (I-J) S1P levels in the plasma (G, n = 6) and in the BM (H, n = 4) at 11AM and 11PM. Error bars, mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, Student's two-tailed unpaired t-test (A, C, G-H), one-way ANOVA with Tukey's post hoc test (E-F). 
CD34
-LSK cells in the BM at 7PM following NE 1h administration compared to 7AM steady state levels (I). Number of BM CMP (J, n = 5) or CLP (K, n = 6) cells per femur, Evans Blue Dye absorbance per femur at 620nm (L, n = 4) and circulating LSK cells: representative plots (M) and data summarized per ml of blood (N, n = 8) at 11PM in NE treated mice compared to 11AM steady state levels. Error bars, mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, Student's two-tailed unpaired t-test (A-C, E-F), one-way ANOVA with Tukey's post hoc test (I-N). (1), there is a high elevation in BM NE levels (2) leading to TNF augmentation (3) via β2AR on HSPC and monocytes. Together, NE and TNF increase ROS levels in HSPC (4), known to exert their proliferation, differentiation and egress to the circulation (5). At the same time NE further elevates BM vessel permeability via β3AR to facilitate mature and immature cell egress at 11AM (6). Thus the morning peak involves proliferation, differentiation and egress with high BM blood vessel permeability, all associated with a state of increased migration, development and blood replenishment. Following termination of light (7) NE (8), TNF (9) and ROS (10) are elevated, however to a lower extent then in the morning, enabling proliferation without differentiation and egress of HSPC. More importantly, nocturnal melatonin levels are elevated in the BM (11). Melatonin decreases vascular permeability (12) and elevates COX-2/αSMA macrophages (13). As such, melatonin primes HSPC to a state of retention, reduced differentiation and higher CD150 surface expression and repopulation potential (14).
